Hide-and-seek: The challenge of viral persistence in HIV-1 infection

Annual Review of Medicine

Volumn 59, Issue , 2008, Pages 487-501

  Geeraert, Luc ^a   Kraus, Günter ^a   Pomerantz, Roger J ^b  

^a TIBOTEC BVBA   (Belgium)

^b Tibotec Inc   (United States)

Author keywords

Eradication; HAART; Latency; Viral reservoir

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; CD45RO ANTIGEN; CYCLOPHOSPHAMIDE; DARUNAVIR; DIDANOSINE; ELVITEGRAVIR; ENFUVIRTIDE; ETRAVIRINE; GAMMA INTERFERON; HYDROXYUREA; INTERLEUKIN 2; INTERLEUKIN 6; OKT 3; PROTEINASE INHIBITOR; RALTEGRAVIR; RILPIVIRINE; TIPRANAVIR; TUMOR NECROSIS FACTOR ALPHA; VALPROIC ACID;

CD4+ T LYMPHOCYTE; CLINICAL TRIAL; DRUG EFFICACY; DRUG WITHDRAWAL; ERADICATION THERAPY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGICAL MEMORY; LOW DRUG DOSE; NONHUMAN; PERSISTENT VIRUS INFECTION; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME; VIRUS CELL INTERACTION; VIRUS LATENCY; VIRUS LOAD;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; HIV INFECTIONS; HIV-1; HUMANS; TREATMENT FAILURE; VIRUS ACTIVATION; VIRUS LATENCY;

EID: 39649105458     PISSN: 00664219     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.med.59.062806.123001     Document Type: Review

References (93)

1. Pomerantz RJ, Horn DL. 2003. Twenty years of therapy for HIV-1 infection. Nat. Med. 9:867-73
2. Gulick RM, Mellors JW, Havlir D, et al. 1997. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N. Engl. J. Med. 337:734-39
3. Cavert W, Notermans DW, Staskus K, et al. 1997. Kinetics of response in lymphoid tissues to antiretroviral therapy of HIV-1 infection. Science 276:960-64
4. Perelson AS, Essunger P, Cao Y, et al. 1997. Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 387:188-91
5. Wong JK, Hezareh M, Günthard HF, et al. 1997. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 278:1291-95
6. Chun T-W, Stuyver L, Mizell SB, et al. 1997. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc. Natl. Acad. Sci. USA 94:13193-97
7. Finzi D, Hermankova M, Pierson T, et al. 1997. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 278:1295-300
8. Chun T-W, Carruth L, Finzi D, et al. 1997. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 387:183-88
9. Chun TW, Finzi D, Margolick J, et al. 1995. In vivo fate of HIV-1-infected T cells: quantitative analysis of the transition to stable latency. Nat. Med. 1:1284-90
10. Coffin JM. 1995. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 267:483-89
11. Wei X, Ghosh SK, Taylor ME, et al. 1995. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 373:117-22
12. Ho DD, Neumann AU, Perelson AS, et al. 1995. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373:123-26
13. Michie CA, McLean A, Alcock C, et al. 1992. Lifespan of human lymphocyte subsets defined by CD45 isoforms. Nature 360:264-65
14. Mclean AR, Michie CA. 1995. In vivo estimates of division and death rates of human T lymphocytes. Proc. Natl. Acad. Sci. USA 92:3707-11
15. + T cells. Nat. Med. 9:727-28
16. + T lymphocytes in infected children. J. Clin. Invest. 105:995-1003
17. Verhofstede C, Noe A, Demecheleer E, et al. 2004. Drug-resistant variants that evolve during nonsuppressive therapy persist in HIV-1-infected peripheral blood mononuclear cells after long-term highly active antiretroviral therapy. J. Acquir. Immune Defic. Syndr. 35:473-83
18. Lambotte O, Chaix M-L, Gubler B, et al. 2004. The lymphocyte HIV reservoir in patients on long-term HAART is a memory of virus evolution. AIDS 18:1147-58
19. Ramratnam B, Mittler JE, Zhang L, et al. 2000. The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged antiretroviral therapy. Nat. Med. 6:82-85
20. Harrigan PR, Whaley M, Montaner JSG. 1999. Rate of HIV-1 RNA rebound upon stopping antiretroviral therapy. AIDS 13:F59-F62
21. Perelson AS, Neumann AU, Markowitz M, et al. 1996. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 271:1582-86
22. Gartner S, Markovits P, Markovitz DM, et al. 1986. The role of mononuclear phagocytes in HTLV-III/LAV infection. Science 233:215-19
23. Sonza S, Mutimer HP, Oelrichs R, et al. 2001. Monocytes harbour replication-competent, nonlatent HIV-1 in patients on highly active antiretroviral therapy. AIDS 15:17-22
24. Haase AT, Henry K, Zupancic M, et al. 1996. Quantitative image analysis of HIV-1 infection in lymphoid tissue. Science 274:985-89
25. Hlavacek WS, Stilianakis NI, Notermans DW, et al. 2000. Influence of follicular dendritic cells on decay of HIV during antiretroviral therapy. Proc. Natl. Acad. Sci. USA 97:10966-71
26. Zack JA, Arrigo SJ, Weitsman SR, et al. 1990. HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure. Cell 61:213-22
27. Bukrinsky MI, Stanwick TL, Dempsey MP, et al. 1991. Quiescent T lymphocytes as an inducible virus reservoir in HIV-1 infection. Science 254:423-27
28. + T cells. J. Virol. 79:2199-210
29. Pierson TC, Zhou Y, Kieffer TL, et al. 2002. Molecular characterization of preintegration latency in human immunodeficiency virus type 1 infection. J. Virol. 76:8518-31
30. Finzi D, Siliciano RF. 1998. Viral dynamics in HIV-1 infection. Cell 93:665-71
31. Dornadula G, Zhang H, VanUitert B, et al. 1999. Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy. JAMA 282:1627-32
32. Di Mascio M, Dornadula G, Zhang H, et al. 2003. In a subset of subjects on highly active antiretroviral therapy, human immunodeficiency virus type 1 RNA in plasma decays from 50 to <5 copies per milliliter, with a half-life of 6 months. J. Virol. 77:2271-75
33. Strain MC, Gunthard HF, Havlir DV, et al. 2003. Heterogeneous clearance rates of long-lived lymphocytes infected with HIV: intrinsic stability predicts lifelong persistence. Proc. Natl. Acad. Sci. USA 100:4819-24
34. + T cells during primary HIV-1 infection. Proc. Natl. Acad. Sci. USA 95:8869-73
35. Pierson T, Hoffman TL, Blankson J, et al. 2000. Characterization of chemokine receptor utilization of viruses in the latent reservoir for human immunodeficiency virus type 1. J. Virol. 74:7824-33
36. Brooks DG, Kitchen SG, Kitchen CMR, et al. 2001. Generation of HIV latency during thymopoiesis. Nat. Med. 7:459-64
37. + T cells. J. Virol. 80:6441-57
38. + T cell depletion and viral replication in SIV infection. Science 280:427-31
39. Marras D, Bruggeman LA, Gao F, et al. 2002. Replication and compartmentalization of HIV-1 in kidney epithelium of patients with HIV-associated nephropathy. Nat. Med. 8:522-26
40. Pomerantz RJ, Kuritzkes DR, de la Monte SM, et al. 1987. Infection of the retina by human immunodeficiency virus type I. N. Engl. J. Med. 317:1643-47
41. Zhang H, Dornadula G, Beumont M, et al. 1998. Human immunodeficiency virus type 1 in the semen of men receiving highly active antiretroviral therapy. N. Engl. J. Med. 339:1803-9
42. Koenig S, Gendelman HE, Orenstein JM, et al. 1986. Detection of AIDS virus in macrophages in brain tissue from AIDS patients with encephalopathy. Science 233:1089-93
43. + T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat. Med. 5:512-17
44. Schroder ARW, Shinn P, Chen H, et al. 2002. HIV-1 integration in the human genome favors active genes and local hotspots. Cell 110:521-29
45. + T cells from human immunodeficiency virus type 1 (HIV-1)-infected individuals carry integrated HIV-1 genomes within actively transcribed host genes. J. Virol. 78:6122-33
46. Katz RA, Gravuer K, Skalka AM. 1998. A preferred target DNA structure for retroviral integrase in vitro. J. Biol. Chem. 273:24190-95
47. Jordan A, Defechereux P, Verdin E. 2001. The site of HIV-1 integration in the human genome determines basal transcriptional activity and response to Tat transactivation. EMBO J. 20:1726-38
48. Stevens M, De Clercq E, Balzarini J. 2006. The regulation of HIV-1 transcription: molecular targets for chemotherapeutic intervention. Med. Res. Rev. 26:595-625
49. Zhou M, Halanski MA, Radonovich MF, et al. 2000. Tat modifies the activity of CDK9 to phosphorylate serine 5 of the RNA polymerase II carboxyl-terminal domain during human immunodeficiency virus type 1 transcription. Mol. Cell Biol. 20:5077-86
50. Kao SY, Calman AF, Luciw PA, et al. 1987. Anti-termination of transcription within the long terminal repeat of HIV-1 by tat gene product. Nature 330:489-93
51. Yankulov K, Blau J, Purton T, et al. 1994. Transcriptional elongation by RNA polymerase II is stimulated by transactivators. Cell 77:749-59
52. Laspia MF, Rice AP, Mathews MB. 1989. HIV-1 Tat protein increases transcriptional initiation and stabilizes elongation. Cell 59:283-92
53. Zhou Q, Chen D, Pierstorff E, et al. 1998. Transcription elongation factor P-TEFb mediates Tat activation of HIV-1 transcription at multiple stages. EMBO J. 17:3681-91
54. Marshall NF, Price DH. 1995. Purification of P-TEFb, a transcription factor required for the transition into productive elongation. J. Biol. Chem. 270:12335-38
55. Nabel G, Baltimore D. 1987. An inducible transcription factor activates expression of human immunodeficiency virus in T cells. Nature 326:711-13
56. Kinoshita S, Su L, Amano M, et al. 1997. The T cell activation factor NF-ATc positively regulates HIV-1 replication and gene expression in T cells. Immunity 6:235-44
57. Osborn L, Kunkel S, Nabel GJ. 1989. Tumor necrosis factor alpha and interleukin 1 stimulate the human immunodeficiency virus enhancer by activation of the nuclear factor κB. Proc. Natl. Acad. Sci. USA 86:2336-40
58. + T cells: involvement of NF-κB activation. Virology 361:325-34
59. Tong-Starksen SE, Luciw PA, Peterlin BM. 1987. Human immunodeficiency virus long terminal repeat responds to T-cell activation signals. Proc. Natl. Acad. Sci. USA 84:6845-49
60. Jordan A, Bisgrove D, Verdin E. 2003. HIV reproducibly establishes a latent infection after acute infection of T cells in vitro. EMBO J. 22:1868-77
61. Verdin E, Paras PJ, Van Lint C, 1993. Chromatin disruption in the promoter of human immunodeficiency virus type 1 during transcriptional activation. EMBO J. 12:3249-59
62. Van Lint C, Emiliani S, Ott M, et al. 1996. Transcriptional activation and chromatin remodeling of the HIV-1 promoter in response to histone acetylation. EMBO J. 15:1112-20
63. Ramratnam B, Ribeiro R, He T, et al. 2004. Intensification of antiretroviral therapy accelerates the decay of the HIV-1 latent reservoir and decreases, but does not eliminate, ongoing virus replication. J. Acquir. Immune Defic. Syndr. 35:33-37
64. Havlir DV, Strain MC, Clerici M, et al. 2003. Productive infection maintains a dynamic steady state of residual viremia in human immunodeficiency virus type 1-infected persons treated with suppressive antiretroviral therapy for five years. J. Virol. 77:11212-19
65. Kim H, Perelson AS. 2006. Viral and latent reservoir persistence in HIV-1-infected patients on therapy. PLoS Comput. Biol. 2:1232-47
66. Folks TM, Justement J, Kinter A, et al. 1987. Cytokine-induced expression of HIV-1 in a chronically infected promonocyte cell line. Science 238:800-2
67. + T cells using a combination of cytokines. J. Exp. Med. 188:83-91
68. + T cells in HIV-1-infected patients receiving highly active antiretroviral therapy. Nat. Med. 5:651-55
69. Weidmann E, Bergmann L, Stock J, et al. 1992. Rapid cytokine release in cancer patients treated with interleukin-2. J. Immunother. 12:123-31
70. Chun T-W, Davey RT Jr, Engel D, et al. 1999. Re-emergence of HIV after stopping therapy. Nature 401:874-75
71. Davey RT Jr, Bhat N, Yoder C, et al. 1999. HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression. Proc. Natl. Acad. Sci. USA 96:15109-14
72. Stellbrink H-J, van Lunzen J, Westby M, et al. 2002. Effects of interleukin-2 plus highly active antiretroviral therapy on HIV-1 replication and proviral DNA (COSMIC trial). AIDS 16:1479-87
73. Lafeuillade A, Poggi C, Chadapaud S, et al. 2001. Pilot study of a combination of highly active antiretroviral therapy and cytokines to induce HIV-1 remission. J. Acquir. Immune Defic. Syndr. 26:44-55
74. + T cell depletion. J. Clin. Immunol. 21:218-26
75. Fraser C, Ferguson NM, Ghani AC, et al. 2000. Reduction of the HIV-1-infected T-cell reservoir by immune activation treatment is dose-dependent and restricted by the potency of antiretroviral drugs. AIDS 14:659-69
76. Prins JM, Jurriaans S, van Praag RME, et al. 1999. Immuno-activation with anti-CD3 and recombinant human IL-2 in HIV-1-infected patients on potent antiretroviral therapy. AIDS 13:2405-10
77. Lori F, Malykh A, Cara A, et al. 1994. Hydroxyurea as an inhibitor of human immunodeficiency virus-type 1 replication. Science 266:801-5
78. De Boer RJ, Boucher CA, Perelson AS. 1998. Target cell availability and the successful suppression of HIV by hydroxyurea and didanosine. AIDS 12:1567-70
79. Chapuis AG, Rizzardi GP, D'Agostino C, et al. 2000. Effects of mycophenolic acid on human immunodeficiency virus infection in vitro and in vivo. Nat. Med. 6:762-68
80. Kulkosky J, Nunnari G, Otero M, et al. 2002. Intensification and stimulation therapy for human immunodeficiency virus type 1 reservoirs in infected persons receiving virally suppressive highly active antiretroviral therapy. J. Infect. Dis. 186:1403-11
81. Nunnari G, Leto D, Sullivan J, et al. 2005. Seminal reservoirs during an HIV type 1 eradication trial. AIDS Res. Hum. Retroviruses 21:768-75
82. Berger EA, Moss B, Pastan I. 1998. Reconsidering targeted toxins to eliminate HIV infection: you gotta have HAART. Proc. Natl. Acad. Sci. USA 95:11511-13
83. Deeks SG, Wagner B, Anton PA, et al. 2002. A phase II randomized study of HIV-specific T-cell gene therapy in subjects with undetectable plasma viremia on combination antiretroviral therapy. Mol. Ther. 5:788-97
84. Bartlett JA, Miralles GD, Sevin AD, et al. 2002. Addition of cyclophosphamide to antiretroviral therapy does not diminish the cellular reservoir in HIV-infected persons. AIDS Res. Hum. Retroviruses 18:535-43
85. McCoig C, Van Dyke G, Chou C-S, et al. 1999. An anti-CD45RO immunotoxin eliminates T cells latently infected with HIV-1 in vitro. Proc. Natl. Acad. Sci. USA 96:11482-85
86. Kulkosky J, Culnan DM, Roman J, et al. 2001. Prostratin: activation of latent HIV-1 expression suggests a potential inductive adjuvant therapy for HAART. Blood 98:3006-15
87. Korin YD, Brooks DG, Brown S, et al. 2002. Effects of prostratin on T-cell activation and human immunodeficiency virus latency. J. Virol. 76:8118-23
88. Ylisastigui L, Archin NM, Lehrman G, et al. 2004. Coaxing HIV-1 from resting CD4 T cells: histone deacetylase inhibition allows latent viral expression. AIDS 18:1101-8
89. Lehrman G, Hogue IB, Palmer S, et al. 2005. Depletion of latent HIV-1 infection in vivo: a proof-of-concept study. Lancet 366:549-55
90. Siliciano JD, Lai J, Callender M, et al. 2007. Stability of the latent reservoir for HIV-1 in patients receiving valproic acid. J. Infect. Dis. 195:833-36
91. Steel A, Clark S, Teo I, et al. 2006. No change to HIV-1 latency with valproate therapy. AIDS 20:1681-82
92. Triboulet R, Mari B, Lin Y-L, et al. 2007. Suppression of microRNA-silencing pathway by HIV-1 during virus replication. Science 315:1579-82
93. Williams SA, Chen L-F, Kwon H, et al. 2006. NF-κB p50 promotes HIV latency through HDAC recruitment and repression of transcriptional initiation. EMBO J. 25:139-49